Searched for
BIOSIMILARS AND MEDICAL DEVICES
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- Sun Pharma shares tumble 4% as firm closes in on $12-billion Organon acquisition. What’s spooking investors?Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & ...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Zydus Lifesciences in focus after USFDA clears Ahmedabad plant, Aflibercept biosimilar launchZydus Lifesciences is in focus after receiving USFDA clearance with zero observations for its Ahmedabad facility and launching ANYRA, India...
- Biopharma Shakti: India targets China dependence, patent cliffIndia is launching a major initiative to boost its biopharmaceutical manufacturing. This plan aims to reduce reliance on China for crucial ...
- Eco Survey: Pharma focus turns to value, innovation over volumesIndia's pharma sector is moving towards high-value products like complex generics and biosimilars. The medical devices industry is also gro...
- Budget 2026: Pharma, med-tech companies seek PLI extension to cover APIsThe industry expects the government to address these issues in the Union budget announcement this year. Sudarshan Jain, secretary general o...
- Odisha unveils pharmaceutical and medical devices policy to bring Rs 25,000 crore investment by 2030Chief Minister Mohan Charan Majhi launched the new policy here at the Odisha Pharma Summit-2025 in the presence of Industries Minister Samp...
- India-UK FTA prescribes a booster dose for Indian pharma and medtech exportsThe India-UK FTA is poised to significantly boost India's pharmaceutical and medical device sectors. Tariff relief and streamlined regulati...
- Duty relief to boost pharma companies' access to UK drug storesThe India-UK Free Trade Agreement is set to significantly benefit India's pharma and medical device industries. Tariff reductions and strea...
- J&J acquires experimental skin disorder drug for $1.25 billionNUMAB THERAPEUTICS-JOHNSON&JOHNSON/M&A (UPDATE 2, PIX)UPDATE 2-J&J acquires experimental skin disorder drug for $1.25 billion
- J&J Q4 Results: Profit edges past Street view after deals delay Stelara competitionJohnson & Johnson on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psor...
- India, Colombia exchange views on cooperation in biotechnology sectorThere was a mutual exchange of views on possible areas of scientific cooperation in the biotechnology sector, the Science and Technology mi...
- Lupin, Nichi-Iko tie up for commercialization of biosimilar Etanercept in JapanMumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin’s recently-filed biosimilar ...
- Take Solutions to acquire Ecron Acunova for Rs 115 croreTake would also be able to expand its IPs in risk-based monitoring and other solutions aimed at bringing safe, effective, and affordable dr...
- Ranbaxy plans to launch growth hormone drugRanbaxy Laboratories is planning a new growth hormone product to target the emerging global market for new versions of patent-expired biote...
Load More
